Evidence map›Paper›PMID 28396092›Full record

ReviewPharmacological research2017

Targeting the unfolded protein response in cancer.

Rani Ojha, Ravi K Amaravadi

Abstract readReview
In one paragraph

Review in Pharmacological research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 134 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. XBP1 promotes NRASJournal of cellular and molecular medicine · 2023
    Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rani OjhaDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, United States.
Ravi K AmaravadiDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, United States. Electronic address: Ravi.amaravadi@uphs.upenn.edu.
University of Pennsylvania · US

Funding

Molecular mechanisms of BRAF inhibitor induced UPR and autophagyR01CA198015 · NCI · UNIVERSITY OF PENNSYLVANIA · PI AMARAVADI, RAVI K · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA198015
6 · The paper itself

Abstract

Cancer cells are exposed to various intrinsic and extrinsic factors that disrupt protein homeostasis, producing endoplasmic reticulum (ER) stress. To cope with these situations, cancer cells evoke a highly conserved adaptive mechanism called the unfolded protein response (UPR) to restore the ER homeostasis. Recently, several pharmacological agents have been found to exhibit anti-tumor activity by targeting the UPR components. The development of potent and specific compounds that target the UPR components has not only shed light on the regulation of the UPR in cancer cells, but also brought the field closer to clinical drug candidates. Here we present an overview of the milestones in the field of UPR biology in cancer with a focus on new strategies for pharmacological inhibition.

Indexed as

AnimalsAntineoplastic AgentsDrug DiscoveryEndoplasmic Reticulum StressHumansMolecular Targeted TherapyNeoplasmsUnfolded Protein ResponseAntineoplastic AgentsAnticancer therapyCancerEndoplasmic reticulum stressUnfolded protein response

Identifiers

PMID28396092
PMCPMC5542584
OpenAlexW2605011382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.